Table 2.
Demographics and wound characteristics at study enrollment
| BSS (n = 33) | dHACM (n = 32) | SWC (n = 35) | |
|---|---|---|---|
| Age (years) | 63·8 (11·86) | 63·3 (12·25) | 60·6 (11·55) |
| Age ≥ 65 years | 17 (16·8%) | 17 (16·8%) | 12 (11·9%) |
| Gender: male | 14 (13·9%) | 19 (18·8%) | 22 (21·8%) |
| Race | |||
| Caucasian | 30 (29·7%) | 31 (30·7%) | 31 (30·7%) |
| African‐American | 3 (3·0%) | 2 (2·0%) | 3 (3·0%) |
| Smoker | 6 (18·2%) | 9 (28·1%) | 12 (34·3%) |
| Hx Hypertension | 24 (72·7%) | 22 (68·8%) | 26 (74·3%) |
| Hx CAD | 5 (15·2%) | 6 (18·8%) | 10 (28·6%) |
| Hx CHF | 5 (15·2%) | 2 (6·3%) | 3 (8·6%) |
| Hx Prior DFU | 23 (69·7%) | 20 (62·5%) | 20 (57·1%) |
| Plantar Ulcer | 26 (78·8%) | 25 (78·1%) | 32 (91·4%) |
| Ulcer Location | |||
| Toe | 14 (42·4%) | 9 (28·1%) | 11 (31·4%) |
| Forefoot | 11 (33·3%) | 9 (28·1%) | 12 (34·3%) |
| Midfoot | 4 (12·1%) | 8 (25·0%) | 6 (17·1%) |
| Hindfoot/ankle | 4 (12·1%) | 6 (18·8%) | 6 (17·1%) |
| Body mass index |
33·3 (8·92) 31·0 (17·72, 58·91) |
33·9 (6·99) 34·1 (23·09, 48·42) |
34·7 (9·35) 33·4 (20·12, 64·01) |
| Body mass index ≥ 30 | 20 (19·8%) | 20 (19·8%) | 23 (22·8%) |
| HbA1c |
7·9 (1·79) 7·5 (5·4, 11·9) |
7·5 (1·51) 7·4 (5·5, 11·2) |
8·2 (1·78) 8·3 (5·5, 11·8) |
| HbA1c ≥ 9% | 8 (7·9%) | 5 (4·9%) | 11 (10·9%) |
| Hx of index ulcer (weeks) |
19·0 (14·78) 16 (4, 52) |
17·3 (15·3) 12 (3·52) |
14·1 (12·9) 8 (2, 50) |
| Baseline wound size (cm2) |
2·7 (2·75) 1·7 (1·0, 14·7) |
2·6 (2·97) 1·7 (1·0, 16·9) |
3·1 (3·17) 1·8 (1·0, 15·5) |
Data presented as mean (standard deviation), median (minimum, maximum) or number (%) as indicated.
BSS, bioengineered skin substitutes; CAD, coronary artery disease; CHF, congestive heart failure; dHACM, dehydrated human amnion/chorion membrane; DFU, diabetic foot ulcer; SWC, standard wound care.